XP 13512, a prodrug of gabapentin, provides clinical benefit in restless legs syndrome (RLS)

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1471, 2005-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gabapentin enacarbil (XP13512/GSK1838262) as an alternative treatment to dopaminergic agents for restless legs syndrome

By Imamura Susan   Kushida Clete  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 11, 2010-08 ,pp. : 1925-1932

Informa Healthcare

Access to resources Recommend Favorite

Gabapentin is effective in treating restless legs syndrome

By  

Inpharma, Vol. 1, Iss. 1300, 2001-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Gabapentin enacarbil has restless legs syndrome up in arms

By  

Inpharma, Vol. 1, Iss. 1649, 2008-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

The Restless Legs Syndrome Quality of Life Instrument (RLS-QLI) is a "reliable and valid" tool for assessing the impact of RLS on patients' lives

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 452, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) - Acute placebo-controlled sleep laboratory studies with clonazepam

By Saletu M.   Anderer P.   Saletu-Zyhlarz G.   Prause W.   Semler B.   Zoghlami A.   Gruber G.   Hauer C.   Saletu B.  

European Neuropsychopharmacology, Vol. 11, Iss. 2, 2001-04 ,pp. : 153-161

Elsevier

Access to resources Recommend Favorite